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Erectile dysfunction affects millions of men worldwide. Twin
studies support the role of genetic risk factors underlying erectile
dysfunction, but no specific genetic variants have been identified.
We conducted a large-scale genome-wide association study of
erectile dysfunction in 36,649 men in the multiethnic Kaiser Per-
manente Northern California Genetic Epidemiology Research in
Adult Health and Aging cohort. We also undertook replication
analyses in 222,358 men from the UK Biobank. In the discovery
cohort, we identified a single locus (rs17185536-T) on chromosome
6 near the single-minded family basic helix-loop-helix transcription
factor 1 (SIM1) gene that was significantly associated with the risk
of erectile dysfunction (odds ratio = 1.26, P = 3.4 × 10−25). The
association replicated in the UK Biobank sample (odds ratio = 1.25,
P = 6.8 × 10−14), and the effect is independent of known erectile
dysfunction risk factors, including body mass index (BMI). The risk
locus resides on the same topologically associating domain as
SIM1 and interacts with the SIM1 promoter, and the rs17185536-
T risk allele showed differential enhancer activity. SIM1 is part of
the leptin–melanocortin system, which has an established role in
body weight homeostasis and sexual function. Because the vari-
ants associated with erectile dysfunction are not associated with
differences in BMI, our findings suggest a mechanism that is spe-
cific to sexual function.
genome-wide association | erectile dysfunction | SIM1 | genetic |
melanocortin
Erectile dysfunction is a common and costly disease of men inmiddle and older ages (1, 2). Its pathophysiology is tied to
psychosocial, neurological, hormonal, and vascular factors (3).
Epidemiological studies have shown that age, obesity, diabetes,
benign prostatic hyperplasia (BPH), lower urinary tract symp-
toms, hyperlipidemia, cardiovascular disease, and smoking are
important risk factors in erectile dysfunction susceptibility (4).
There is also substantial evidence that genetics influence the risk
of erectile dysfunction. A twin study in middle-aged male
veterans found that about one-third of the risk is heritable,
independent of known erectile dysfunction risk factors (5).
However, subsequent association studies searching for specific
genetic contributors have been limited by small sample sizes, a
reliance on limited candidate-gene approaches, and weak phe-
notyping. As a result, there are no confirmed genetic risk factors
for erectile dysfunction (6). Understanding the genetic basis of
erectile dysfunction can provide insight into its etiology and lead
to the development of new therapies.
Here, we undertook a genome-wide association study
(GWAS) of erectile dysfunction in the large and ethnically di-
verse Genetic Epidemiology Research in Adult Health and Ag-
ing (GERA) cohort, which includes 36,649 men from four race/
ethnicity groups (non-Hispanic whites, Hispanic/Latinos, East
Asians, and African Americans). We then validated genome-
wide significant associations in an external independent cohort
of 222,358 men from the UK Biobank. We further examined the
effect of the validated risk locus in race/ethnicity and phenotype
subgroups. Finally, through in silico and in vitro functional in-
vestigations, we linked our risk locus to gene function.
Results
The GERA Cohort. We conducted the primary-discovery erectile
dysfunction GWAS using the survey phenotype definition in
36,349 men from four race/ethnicity groups (non-Hispanic
whites, 81.4%; Hispanic/Latinos, 8.1%; East Asians, 7.5%; and
African Americans, 3.0%) in the GERA cohort (Table 1). Cases
were older than controls (68.9 ± 10.8 vs. 56.1 ± 11.4 y), had
slightly higher body mass indices (BMIs) (27.7 ± 4.7 vs. 26.9 ±
4.3), were more likely to have diabetes (29.8% vs. 14.6%), and
were more likely to be current smokers (6.2% vs. 5.5%) or
former smokers (53.1% vs. 37.2%). Cases were also more likely
than controls to have a clinical diagnosis recorded in the elec-
tronic health record (EHR) (39.3% vs. 23.3%) and were more
likely to have filled a phosphodiesterase type 5 inhibitor (PDE5i)
prescription to treat erectile dysfunction (59.2% vs. 29.0%).
Significance
Erectile dysfunction is a common condition of men in middle
and older ages. Twin studies suggest that about one-third of
the risk is due to genetic factors, independent of other known
erectile dysfunction risk factors. However, studies that have
searched for specific genetic contributors have been limited
due to small sample sizes, candidate gene approaches, and
weak phenotyping. As a result, there are no confirmed genetic
risk factors for erectile dysfunction. This study finds a specific
genetic cause for erectile dysfunction.
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Discovery of an Erectile Dysfunction Risk Locus in the GERA Cohort
and Replication in the UK Biobank Cohort. In our discovery multi-
ethnic GWAS analysis, we identified a single locus on chromosome
6 with multiple noncoding SNPs that were associated at a genome-
wide level of significance with erectile dysfunction (P < 5 × 10−8)
(Fig. 1). To prioritize associated SNPs for follow up analyses, we
used a Bayesian approach to derive the smallest set of variants that
included the causal variant with 95% probability (95% credible set)
(7). Five SNPs were included in this 95% credible set (SI Appendix,
Table S1). We then conducted a replication association analysis of
these five SNPs in an independent cohort of 222,358 men (2,957
cases and 219,401 controls) from the UK Biobank (SI Appendix,
Table S2). All five credible set SNPs were significantly associated
with erectile dysfunction in the replication analysis (P < 0.01 re-
quired for multiple testing; all SNPs were associated P < 10−13) in
the same direction as the GERA cohort results (SI Appendix,
Table S3). As evolutionary conservation is a strong marker of
functional genomic sequences, we focused our follow-up analyses
on one of the five SNPs, rs17185536, which was the only SNP lo-
cated in an evolutionarily conserved region (8).
Subgroup and Sensitivity Analyses Show That the Association of
rs17185536 Is Independent of Known Erectile Dysfunction Risk
Factors. To investigate whether the effect of the replicated
erectile dysfunction risk locus was influenced by race/ethnicity,
we examined the association of rs17185536 separately by GERA
race/ethnicity group. The T allele of rs17185536 (rs17185536-T)
was associated with an increase in the risk of erectile dysfunction
in non-Hispanic whites (odds ratio 1.25, 95% CI 1.19–1.31),
Hispanic/Latinos (odds ratio 1.35, 95% CI 1.16–1.57), East
Asians (odds ratio 1.05, 95% CI 0.65–1.71), and African Amer-
icans (odds ratio 1.36, 95% CI 1.07–1.71) (SI Appendix, Fig.
S1A). While the association was not significant (P > 0.05) in the
East Asian group, this appears to be due to the lower frequency
of the T allele in that group (2%) than in the other race/ethnicity
groups (26% in non-Hispanic whites, 19% in Hispanic/Latinos,
and 21% in African Americans). We also examined the associ-
ation of rs17185536 by decade of age. We observed significant
associations across each decade, with the strongest effect in men
aged 50–59 y (odds ratio 1.32, 95% CI 1.24–1.41).
Because the risk of erectile dysfunction has been associ-
ated with a number of other risk factors, including higher BMI,
diabetes, benign prostatic hyperplasia, lower urinary tract
symptoms, hyperlipidemia, cardiovascular disease, and smoking
status, we conducted analyses adjusting for each of these risk
factors individually and combined in GERA to determine
whether the risk locus imparted its effect via one of these risk
factors. After adjusting for BMI, the effect of rs17185536-T
remained similar to the overall GERA result (odds ratio 1.26,
95% CI 1.21–1.32) (SI Appendix, Fig. S1B), which is consistent
with a lack of association between the SNP and BMI (P = 0.51).
Similarly, the association between rs17185536 and erectile dys-
function was similar after adjusting for the other risk factors
individually and in a model including all risk factors as covariates
at the same time (odds ratio 1.27, 95% CI 1.21–1.33), suggesting
that these risk factors do not explain the observed association. In
the fully adjusted model, rs17185536 explained 1.6% of the
heritability of the risk of ED. Finally, we used LD Hub to con-
duct a genetic correlation analysis with 177 traits with available
Table 1. Characteristics of GERA men
Characteristic Control, n = 22,434 Case, n = 14,215 Total, n = 36,649
Race/ethnicity, no. participants (%)
Non-Hispanic whites 17,995 (80.2) 11,864 (83.5) 29,859 (81.5)
Hispanic/Latinos 1,954 (8.7) 1,016 (7.1) 2,970 (8.1)
East Asian 1,799 (8.0) 938 (6.6) 2,737 (7.5)
African American 686 (3.1) 397 (2.8) 1,083 (3.0)
Age, y* 56.1 ± 11.4 68.9 ± 10.8 61.1 ± 12.8
BMI* 26.9 ± 4.3 27.7 ± 4.7 27.2 ± 4.5
Diabetes, no. participants (%)
Yes 3,265 (14.6) 4,240 (29.8) 7,505 (20.5)
No 19,169 (85.4) 9,975 (70.2) 29,144 (79.5)
Smoking history, no. participants (%)†
Never 12,586 (57.2) 5,545 (40.7) 18,131 (50.9)
Former 8,181 (37.2) 7,235 (53.1) 15,416 (43.3)
Current 1,220 (5.5) 841 (6.2) 2,061 (5.8)
EHR diagnosis, no. participants (%)
Yes 5,237 (23.3) 5,591 (39.3) 10,828 (29.5)
No 17,197 (76.7) 8,624 (60.7) 25,821 (70.5)
PDE5i prescription, no. participants (%)
Yes 6,513 (29.0) 8,422 (59.2) 14,935 (40.8)
No 15,921 (71.0) 5,793 (40.8) 21,714 (59.2)
*Age and BMI are presented as means ± SD.
†Some participants (n = 1,041) did not have a smoking history.
Fig. 1. Manhattan plot of the GERA discovery cohort multiethnic genome-
wide association meta-analysis of erectile dysfunction. A GWAS of erectile
dysfunction was conducted in 36,649 men (14,215 cases and 22,434 controls)
from four race/ethnicity groups (non-Hispanic white, Latino, East Asian, and
African American). Association results (−log10 P values) are plotted for each
chromosome. The SIM1 gene name at the locus associated with erectile
dysfunction is indicated.
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GWAS summary statistics (9). After correcting for multiple
testing, there were no significant associations with other traits.
The Association of rs17185536 Is Robust to Changes in Phenotype
Definition. We also conducted sensitivity analyses to determine
whether the effect of this locus was influenced by phenotype defi-
nition. Since the self-reported questionnaire included four severity
levels, we compared the different response levels, using men who
answered that they are “Always” able to get an erection as the
reference group (SI Appendix, Table S4). We observed a greater
effect of rs17185536-T with each increase in severity level, with
odds ratios of 1.15 (1.09–1.21) for the “Usually” group, 1.30 (1.23–
1.38) for the “Sometimes” group, and 1.41 (1.31–1.51) for the
“Never” group (SI Appendix, Fig. S1C). We also observed genome-
wide significant associations between rs17185536-T and an EHR-
based clinical diagnosis of erectile dysfunction (odds ratio 1.12,
95% CI 1.08–1.17) as well as with the use of PDE5i drugs or other
erectile dysfunction treatments (odds ratio 1.16, 95% CI 1.12–1.19).
Finally, because of the incomplete concordance across these dif-
ferent phenotype definitions, we conducted an analysis using a strict
definition of case and control, requiring cases to meet case criteria
for our survey and clinical and treatment definitions and controls to
meet control criteria in all three definitions. We observed an even
stronger association between the rs17185536-T allele and erectile
dysfunction (odds ratio 1.37, 95% CI 1.31–1.43).
rs17185536 Resides in an Enhancer That Interacts with the Promoter
of the Single-Minded Family Basic Helix-Loop-Helix Transcription
Factor 1 (SIM1) Gene. We then undertook chromatin interaction
and evolutionary conservation analyses to determine whether the
region around rs17185536 interacts with nearby genes. Chromosomes
are organized into topologically associating domains (TADs); en-
hancers interact with genes in the same TAD more frequently than
with genes located in other parts of the genome (10). rs17185536
resides within a TAD that includes the genes SIM1, MCHR2,
PRDM13, CCNC, and USP45, indicating that the erectile dys-
function risk locus could interact with one of these genes (10).
However, of those genes, only SIM1 is located within a human–
mouse synteny block that contains rs17185536. This synteny block
is defined at one end by a mouse chromosomal breakpoint ∼93 kb
distal to MCHR2 (11), the next closest gene to rs17185536, which
suggests that the physical proximity of the erectile dysfunction risk
locus and SIM1 has been preserved over evolutionary time (Fig.
2A). Analyses of various chromatin conformation capture assays
using the 3D Genome Browser (12) show that the region around
rs17185536 interacts with the SIM1 promoter (Fig. 2A). Consis-
tent with this interaction, rs17185536 is located within an evolu-
tionarily conserved sequence that has an H3K27ac ChIP-seq peak
in human skeletal muscle cells and myoblasts from ENCODE (13)
data, suggesting that this region may act as an enhancer (Fig. 2B).
We next set out to determine whether the region encom-
passing rs17185536 or other regions nearby that have SNPs in
strong linkage disequilibrium (r2 >0.8) with rs17185536 function as
enhancers and whether the erectile dysfunction-associated
variant(s) might lead to differential enhancer activity. We cloned
six different regions (SI Appendix, Table S5) containing both the
risk and reference alleles into an enhancer assay vector and tested
them for enhancer activity in HEK 293T cells. We chose this
cell line as SIM1 is known to be expressed in the kidney. We
observed differential enhancer activity between the risk and
reference alleles for three of the constructs, including the
rs17185536-T (risk) allele, which showed significant enhancer
activity compared with empty vector, and the rs17185536-C
(reference), which did not have significant enhancer activity
(Fig. 3). Combined, our results suggest that the rs17185536-T
(risk) allele or other erectile dysfunction-associated alleles in
this region lead to differential enhancer activity and that this
region may regulate the expression of SIM1.
Fig. 2. Genomic and epigenetic annotations of the SIM1 locus. (A) A University of California, Santa Cruz genome browser snapshot of the SIM1 locus showing
rs17185536, the TAD in this region, the human–mouse (H–M) synteny breakpoint, and the virtual 4C (circularized chromosome conformation capture) in-
teractions from human GM12878 cells adapted from the 3D Genome Browser (54). (B) A zoomed-in view of the regions that were cloned for enhancer assays
showing the cloned regions, the SNPs, the ENCODE human skeletal muscle cells and myoblasts ChIP-seq peaks (green), ENCODE DNaseI hypersensitivity sites,
ENCODE transcription factor ChIP-seq sites, and evolutionary conservation peaks (blue peaks) (B).
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Discussion
We identified a single locus near the SIM1 gene that was signifi-
cantly associated with the risk of erectile dysfunction and con-
firmed that association in a large, independent cohort. The association
was robust to changes in phenotype definition and was independent of
known erectile dysfunction risk factors. Through a series of analyses,
we showed that the region containing the lead variant likely interacts
with the promoter of the SIM1 gene and that the risk allele of the lead
variant alters an enhancer.
Several different lines of evidence suggest a biologically plausible
role for SIM1 in erectile dysfunction susceptibility. SIM1 encodes a
transcription factor that is active in the leptin–melanocortin path-
way, a system that plays a central role in body weight homeo-
stasis and sexual function (14). The melanocortin peptides alpha
melanocortin-stimulating hormone (α-MSH) and adrenocortico-
trophic hormone (ACTH) have long been known to stimulate pe-
nile erection in male animals (15, 16); MT-II, a synthetic analog of
α-MSH, has been shown to induce penile erection in men (17).
While both MT-II and α-MSH are nonselective melanocortin
agonists, it is believed that their effect on sexual function is mediated
by the melanocortin 4 receptor (MC4R). Mice lacking Mc4r display
impaired copulatory behavior (18), an effect that is reversed when
MC4Rs are reexpressed only on SIM1-expressing neurons (19). In
the latter study, SIM1-dependent expression of MC4R was observed
in the paraventricular nucleus of the hypothalamus and medial
amygdala. Rare mutations in the coding sequences of both MC4R
and SIM1 cause severe forms of human obesity (20), and neurons
coexpressing MC4R and SIM1 in the paraventricular nucleus of the
hypothalamus have been shown to be both necessary and sufficient
for the regulation of feeding and body weight in mice (21).
In our study, the SNPs in the erectile dysfunction risk locus were
not associated with variation in BMI, nor was the effect of this locus
on the risk of erectile dysfunction changed after adjusting for BMI.
We hypothesize that the SIM1 enhancer harboring rs17185536 or the
other erectile dysfunction-associated alleles that show differential
enhancer activity are active in neurons that control erectile function
but not in those controlling feeding and body weight homeostasis.
Melanocortin agonists have been shown to initiate penile erection
when administered in both the brain and the spinal cord (22). De-
termining whether the neurons that are sufficient for erectile func-
tion are located in the brain, the spinal cord, or both will be essential
to understand the specificity of the erectile dysfunction risk locus
identified in this study. Further in vivo analyses of enhancers in this
region have the potential to address these questions.
An important limitation of the current investigation is the po-
tential for phenotype misclassification when using a self-reported,
survey-based phenotype. We addressed this limitation by con-
ducting a number of sensitivity analyses using alternative pheno-
type definitions based on EHRs and replication in an independent
cohort with a different phenotype definition. While the difference
in phenotype definition can reduce power to confirm associations,
we observed strong confirmation of the discovery association,
which provides further support for the robustness of the observed
association to changes in phenotype definition. The incomplete
concordance between the survey, clinical, and treatment-based
phenotype definitions is expected and has been described pre-
viously in the literature (2). Many men with erectile dysfunction
do not seek medical care for the condition. For this reason, the
absence of a clinical diagnosis or PDE5i prescription is not on its
own an indicator of an absence of erectile dysfunction. To limit
the potential presence of cases among our control group, and vice
versa, we conducted an analysis using strict case and controls
definitions in which each strict case met the case criteria for the
survey and clinical and treatment-based phenotype definitions,
and each strict control met the control criteria for all three defi-
nitions. We again observed a significant association with the same
locus, with a modestly stronger effect size.
While MC4R and SIM1 loss of function are associated with
erectile dysfunction, we observed increased enhancer activity for
the rs17185536 erectile dysfunction-associated allele. This could
be due to this SNP not being the causative variant, to interaction
between this variant and other SNPs, or to this region having an
additional, as yet uncharacterized function. Further analyses of
this region will be needed to characterize its functional role.
Another limitation is that we did not have a comparable
phenotype available in women. Based on both human and animal
studies of the effects of melanocortin agonists on sexual function
in females, it is possible that our erectile dysfunction risk locus
may also affect female sexual function, including sexual desire
and sexual arousal (23, 24).
Our study is a large-scale investigation of the genetics of
erectile dysfunction. We anticipate that future studies involving
even larger samples will uncover additional risk loci, providing
further insights into the etiology of erectile dysfunction. Our
functional analyses, along with previous studies in the literature,
point toward a previously unknown mechanism underlying
erectile dysfunction, which opens the possibility of developing
drug therapies with a more specific target. Those treatments may
have the potential to improve sexual function in both men
and women.
Methods
GERA Study Population. We performed a GWAS of erectile dysfunction in
36,349 men from the GERA cohort (Table 1). The full GERA cohort includes
110,266 adult men and women who have provided informed consent as
participants in the Research Program on Genes, Environment, and Health
(RPGEH) drawn from adult (at least 18-y-old) members of the Kaiser Per-
manente Medical Care Plan, Northern California Region (KPNC) (25, 26). The
cohort is diverse, with representation from non-Hispanic white, Hispanic/
Latino, East Asian, and African American race/ethnicity groups. All study
procedures were approved by the Institutional Review Board of the Kaiser
Foundation Research Institute.
Phenotype Definition. Upon enrollment in the study, RPGEH participants an-
swered a health questionnaire. On this survey, male participants were asked the
following question: “Many men have difficulty getting and keeping an erection
(or hard-on) that is rigid enough for satisfactory sexual activity. How would you
describe your experience during the past year? (Without the use of a medication
such as Viagra, Cialis, Levitra, injectable drugs, or penis implant or pump de-
vice.)” Respondents were given a choice of four possible answers: (i) Always able
to get and keep an erection good enough for sexual activity, (ii) Usually able to
get and keep an erection good enough for sexual activity, (iii) Sometimes able
to get and keep an erection good enough for sexual activity, (iv) Never able to
get and keep an erection good enough for sexual activity. For the purpose of
the discovery GWAS, we defined erectile dysfunction cases as those subjects
answering “Sometimes” or “Never” (iii or iv) on the survey and controls as those
Fig. 3. Enhancer assay results in HEK 293T cells. Results for each allele
compared with the empty vector are presented as mean ± SD. ****P <
0.0001; ns, not significant; t test.
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subjects answering “Always” or “Usually” (i or ii) on the survey. This survey
definition of erectile dysfunction has been used in other large-scale studies (27)
and demonstrated reasonable accuracy in detecting erectile dysfunction in men
undergoing a detailed clinical examination (28). Men with a history of prostate
cancer at the time of survey were excluded from the analyses.
Genotyping and Imputation. DNA samples from GERA individuals were
extracted from Oragene kits (DNA Genotek, Inc.) at KPNC and were geno-
typed at the Genomics Core Facility of the University of California, San
Francisco (UCSF). DNA samples were genotyped at over 665,000 SNPs on four
race/ethnicity-specific Affymetrix Axiom arrays (Affymetrix) optimized for
individuals of European, Hispanic/Latino, East Asian, and African American
ancestry (29, 30). Genotype quality-control (QC) procedures for the GERA
samples were performed on an arraywise basis (26). SNPs with an initial
genotyping call rate ≥97%, an allele frequency difference ≤0.15 between
men and women for autosomal markers (even though women were not
included in this analysis), and genotype concordance rate >0.75 across du-
plicate samples were included. About 94% of samples and more than 98%
of genetic markers assayed passed QC procedures. In addition to those QC
criteria, SNPs with genotype call rates <90% were removed.
Imputation was also conducted on an arraywise basis. Following the
prephasing of genotypes with Shape-IT v2.r72719 (31), variants were im-
puted from the cosmopolitan 1000 Genomes Project reference panel (phase I
integrated release; www.internationalgenome.org/) using IMPUTE2 v2.3.0
(32–34). As a QC metric, we used the info r2 from IMPUTE2, which is an es-
timate of the correlation of the imputed genotype to the true genotype
(35). We excluded variants with an imputation r2 <0.3 or a minor allele
frequency (MAF) <1%.
For SNPs that were associated at a genome-wide level of significance in the
genome-wide association analyses, we conducted further QC checks. For
directly genotyped SNPs, we examined missing rates and Hardy–Weinberg
tests in the control group and the overall analysis group. All SNPs in the
associated region had low missing rates (<0.005) and were found to be in
Hardy–Weinberg equilibrium (P > 0.05).
GWAS Analysis and Covariate Adjustment. We first analyzed each of the four
race/ethnicity groups (non-Hispanic whites, Hispanic/Latinos, East Asians, and
African Americans) separately. We performed a logistic regression of erectile
dysfunction case/control status with the covariates age at the time of the
health survey and ancestry as principal components (PCs). The Eigenstrat
method (36) v4.2 was used to calculate the PCs on each of the four race/
ethnicity groups (26). The top 10 ancestry PCs were included as covariates for
the non-Hispanic whites, while the top six ancestry PCs were included for the
other three race/ethnicity groups. We then performed a logistic regression
of the residuals on each SNP using PLINK (37) v1.9 (www.cog-genomics.org/
plink/1.9/) to assess genetic associations. Data from each SNP were modeled
using additive dosages to account for the uncertainty of imputation (38).
We then undertook a GERA meta-analysis of erectile dysfunction to
combine the results of the four race/ethnicity groups using the R (39) package
meta. We calculated fixed-effects summary estimates under an additive
model, and we assessed the heterogeneity index, I2, (0–100%) among
groups as well as Cochrane’s Q heterogeneity statistic.
To identify SNPs for follow-up analyses, we used a Bayesian approach
(CAVIARBF) (7). This approach uses SNP association test statistics and in-
formation on the correlation of individual SNPs to estimate the posterior in-
clusion probability of each individual SNP. These probabilities can be used to
derive the smallest set of SNPs that includes the causal variant with 95%
probability. This set of SNPs is called the “95% credible set.” For the signifi-
cantly associated SNPs in this study, we computed each variant’s ability to ex-
plain the observed signal within a 2-Mb window (±1.0 Mb with respect to the
original lead SNP) to derive the 95% credible set. Previous studies (40, 41) have
used similar approaches to prioritize variants near index SNPs for follow-up.
Sensitivity Analyses. Because BMI, diabetes, benign prostatic hyperplasia, lower
urinary tract symptoms, hyperlipidemia, cardiovascular disease, and cigarette
smoking have previously been reported to be associatedwith the risk of erectile
dysfunction (27), we conducted additional analyses of our top associated
SNPs using these risk factors as covariates. We first assessed each risk factor
individually by including a covariate representing its presence or absence, or in
the case of BMI, the value itself, in the logistic regression model. We also in-
cluded all risk factors together in a single model. For diabetes status at the time
of the health survey, we used the KPNC diabetes registry to identify diabetic
subjects. Registry eligibility is determined by pharmacy prescription for diabetes
medications, abnormal HbA1c or glucose values, and outpatient, emergency
room, and hospitalization diagnoses of diabetes (42, 43). A validation study
found that the registry was 99.5% sensitive for diagnosed diabetes (44). Men
with BPH and lower urinary tract symptoms were defined by an American
Urological Association Score Index of 8 or more, or a clinical diagnosis of BPH
[International Classification of Diseases, Ninth Revision (ICD9) codes of 600.0,
600.2, or 600.9] (45–47). Hyperlipidemia was defined using ICD9 codes 272.0–
272.4 or the prescription of a lipid-lowering drug, and cardiovascular disease
was defined by either revascularization procedures (coronary artery bypass
grafting or vascular stents) or ICD9 codes 410, 411, and 413 (ischemic heart
disease), 431–434 and 436 (stroke), and 402.x1 and 428 (congestive heart fail-
ure) (48–50). For smoking status, we used subjects’ responses to the GERA
health survey to create two variables: Ever/Never, and, within the Ever cate-
gory, Current/Former smokers. Finally, we used LD Hub to conduct a genetic
correlation analysis with 177 traits with available GWAS summary statistics (9).
In addition to the survey-based phenotype definition, we also examined
the association of SNPs identified in the discovery GWAS with alternative
phenotype definitions as sensitivity analyses. The KPNC EHRs contain in-
formation on patient clinical diagnoses as a well as treatment records, in-
cluding prescriptions of PDE5i, alprostadil, Caverject, vacuum erectile devices,
and penile implants used to treat erectile dysfunction. We used this in-
formation to create two additional erectile dysfunction phenotype defini-
tions. For the clinical EHR-based definition, we included individuals with at
least one record of organic erectile dysfunction (ICD9 607.84/ICD10 N529) as
cases and those without such a diagnosis as controls. Using the treatment
records, we defined cases asmenwith one ormore recorded prescription for a
PDE5i or any of the other forms of treatments and those with no recorded
prescription or other treatment as controls. Finally, we created a strict case
and control definition, in which each case had to meet criteria for all three
survey, clinical, and treatment-based definitions and controls also had to
meet the definition of control by all three definitions.
Replication of Significant SNP Associations in the Independent UK Biobank
Cohort. To test genome-wide significant SNPs from the GERA analyses for
replication, we evaluated associations in the multiethnic UK Biobank cohort
(51) which included 222,358 men between the ages of 40 and 69 y from five
race/ethnicity groups (European/white, South Asian, mixed, African British,
and East Asian) (SI Appendix, Table S2). These data have been imputed to
the Haplotype Reference Consortium (www.ukbiobank.ac.uk/). We note
that the GERA data were imputed to the 1,000 Genomes reference panel.
Given that the Haplotype Reference Consortium panel is larger, we would
expect that some SNPs might be captured at a higher imputation r2 than in
the 1,000 Genomes imputed SNPs. Variation in coverage can affect statistical
power; for this reason we examined the imputation r2 of the lead SNPs at
the significantly associated locus (SI Appendix, Table S6) (52). Coverage is
very good for all SNPs across all subsets (r2 ≥ 0.88), which indicates similar
statistical power to resolve associations among these SNPs.
Cases were defined as men with a record of erectile dysfunction (“impo-
tence of organic origin”; UK Biobank record 41202) or self-reporting of any of
the following medications on the medications list (data field 20003): alpros-
tadil, Caverject, sildenafil, Viagra (25, 50, or 100 mg), tadalafil, Cialis (10 mg or
20 mg), vardenafil, or Levitra (5, 10, or 20 mg). The control group included
men who did not report any of these conditions or medications. As in the
GERA analyses, we performed a logistic regression of erectile dysfunction
case/control status using age and ancestry principal components as covariates.
In Silico Analyses. We investigated the functional effects of the associated
variants using three in silico tools. To test SNPs for expression of quantitative
trait locus effects, we queried the Genotype-Tissue Expression (GTEx) Portal
(53). None of the SNPs was contained in the GTEx database. We then queried
HaploReg (8) to identify sequence conservation, enhancer marks, and
changes to regulatory motifs. Finally, we used the 3D Genome Browser (54)
to explore long-range chromatin interactions.
Luciferase Assays. We used a well-established in vitro model system to assess
enhancer function of the five SNPs identified in the credible set analysis and a
sixth SNP (rs57989773) in strong linkage disequilibrium with these five SNPs.
Selected sequences (SI Appendix, Table S5) were PCR amplified from human
genomic DNA, cloned into a pGL4.23 enhancer assay vector (Promega), and
sequence-verified for having either allele. We used an empty pGL4.23 as a
negative control. HEK 293T cells were grown in DMEM (Invitrogen) supple-
mented with FBS 10% (UCSF cell-culture facility), 2 mM of L-glutamine (UCSF
cell-culture facility), and 1% penicillin/streptomycin (UCSF cell-culture facility).
Twenty-four hours before transfection, 50,000 HEK 293T cells were plated out in
24-well plates and were grown up to 70% confluency. Cells were transfected
with 0.75 μg of the assayed plasmid and 0.1 μg of pGL4.73[hRluc/SV40] (Prom-
ega) containing Renilla luciferase to correct for transfection efficiency, using
11022 | www.pnas.org/cgi/doi/10.1073/pnas.1809872115 Jorgenson et al.
X-tremeGENE (Roche) according to the manufacturer’s protocol. Transfections
were performed in quadruplets. Twenty-four hours after transfection, cells
were lysed, and luciferase activity was measured using the Dual-Luciferase
Reporter Assay Kit (Promega). Measurements were performed on a GloMax
96-microplate luminometer (Promega). Each experiment was repeated on
two different days using four technical triplicates and three independent
readings per each technical replicate.
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